gms | German Medical Science

102. Jahrestagung der DOG

Deutsche Ophthalmologische Gesellschaft e. V.

23. bis 26.09.2004, Berlin

Gene-therapeutic possibilities in the eye

Meeting Abstract

Search Medline for

Evidenzbasierte Medizin - Anspruch und Wirklichkeit. 102. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft. Berlin, 23.-26.09.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc04dogSA.11.06

The electronic version of this article is the complete one and can be found online at:

Published: September 22, 2004

© 2004 Schraermeyer.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



During the past few years, the potential use of recombinant viral vectors in the treatment of a number of eye diseases has become a real possibility. Indeed, we are now reaching the stage where some of these vectors or paradigms are being tested in human clinical trials.

Here a summary will be given on what is known so far on the biology and immune response to intraocular injection of three different recombinant viral vectors - the high-capacity "gutless" adenovirus, adeno-associated virus (AAV) and lentivirus, so that we can understand the immunological effects of transgenes and viral vectors on the eye. These seem to be fairly benign, maybe due in part to the unique immunological environment of the eye.

As none of these viruses evoke a cell-mediated response, these vectors hold great promise for the treatment of chronic retinal diseases.